Form 4: Director Ramy Farid Receives Vir Biotechnology Equity

Director Ramy Farid acquired 8,000 restricted stock units and 16,000 stock options as part of Vir Biotechnology's equity incentive plan.

Summary

• Director Ramy Farid was granted 8,000 restricted stock units (RSUs) on May 27, 2026.
• Director Ramy Farid was granted 16,000 stock options with an exercise price of $9.10 per share.
• Both the RSUs and the stock options are scheduled to vest in full on May 27, 2027.
• Following these transactions, the director's direct beneficial ownership of common stock increased to 32,000 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing standard administrative disclosure of director compensation rather than a change in company strategy or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard equity incentive grant indicates ongoing retention of board leadership.

Negatives

• Dilutive impact of new equity grants on existing shareholders, though minor in scale.

Risks

• Future share price volatility could impact the value of the granted options.
• Vesting is contingent upon continued service, creating potential turnover risk if the director departs before May 2027.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of director compensation within the biotechnology sector, where equity-based incentives are standard practice to align board members with long-term corporate performance.

Comparison to Industry Standards

• The grant of RSUs and stock options is consistent with standard corporate governance practices for mid-cap biotechnology firms.
• Vesting schedules of one year for director equity are common in the industry to ensure alignment with annual performance cycles.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity awards on May 27, 2027.

Key Dates

Keywords

Vir Biotechnology, VIR, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation